UK Decision Soon On Pfizer/Flynn’s “Excessive” Phenytoin Price Rises

As the Mylan EpiPen controversy in the US draws yet more attention to price increases on certain pharmaceutical products, an imminent decision by the UK competition authorities should help to clarify what should constitute “excessive” and “unfair” pricing.

Piggy bank — Drug prices: getting the balance right

Sometime this month the UK Competition and Markets Authority is expected to decide whether Pfizer Inc. and Flynn Pharma Ltd. breached competition law by charging "excessive and unfair" prices for the anti-epileptic, phenytoin sodium capsules.

The decision, the latest stage of a formal investigation begun by the CMA in 2013, was originally to have been...